FDA Expands Use of Approved Breast Cancer Drug : RushPRNews - Newswire & Global Press Release Distribution

 
Bookmark and Share

FDA Expands Use of Approved Breast Cancer Drug

February 1, 2010

Washington D.C. (rushPRnews) 02/01/10 — Provides oral regime for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

HER2 is a protein involved in normal cell growth. It is found on some types of cancer cells, including breast cancer cells. In hormone positive breast cancer, the presence of certain hormones contributes to breast cancer growth. In HER2-positive breast cancer, stimulation of the HER2 receptor contributes to cancer cell growth. Breast cancer is the second leading cause of death among women. More than 192,000 women will be diagnosed with breast cancer this year.

“This drug combination of Tykerb plus Femara provides women being treated for advanced breast cancer with an important treatment option. This entirely oral treatment regimen works by targeting both HER2 and the hormone receptors, thereby slowing the cancer cells’ ability to grow or spread,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products, in the FDA’s Center for Drug Evaluation and Research.

Women with HER2-positive disease receiving the Tykerb plus Femara combination more than doubled the time they lived without the cancer progressing compared with those receiving Femara alone (35 weeks vs. 13 weeks). Women in the company sponsored study were randomized to receive Tykerb plus Femara or Femara alone. It is too early to determine whether an improvement in overall survival will be observed in the clinical trial.

Tykerb works by depriving tumor cells of signals needed to grow. Tykerb enters the cell and blocks the function of the HER2 protein.

Tykerb was initially approved in combination with a chemotherapy drug, Xeloda (capecitabine) in 2007. This combination was used to treat women with advanced breast cancer tumors with the HER2 protein who had received prior treatment with chemotherapy drugs, including an anthracycline and a taxane, and Herceptin (trastuzumab), an anti-cancer antibody used to treat HER2-positive advanced breast cancer.

Safety information from this study was consistent with previous Tykerb clinical studies in advanced breast cancer. The most commonly reported side effects of the combination were diarrhea, rash, nausea and fatigue. Treatment with Tykerb also has been associated with decreases in heart function, liver damage, and lung tissue inflammation. Fetal harm may occur if used to treat advanced breast cancer in pregnant women. Patients should talk to their health care provider about the potential side effects, drug interactions, and other medical conditions.

 

Tykerb is marketed by Collegeville, Pa.-based GlaxoSmithKline.
Femara is marketed by Lebanon, Pa.-based Novartis AG.

 

For more information:

 

FDA Office of Oncology Drug Products
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

 

National Cancer Institute – Breast Cancer
http://www.cancer.gov/cancertopics/types/breast

 

RSS Feed for FDA News Releases [what is RSS?]

About the author:

FDA is an agency within the Department of Health and Human Services and consists of seven centers and offices

Click here to see all news from this author/company

Filed Under: FDA- Pharmaceutical news, Health and Fitness, Food-Nutrition, Lifestyle, PRESS RELEASE

RUSH PR NEWS newswire and press release services at rushprnews.com / AH Marketing ahmarketinggroup.com

Content- Legal Responsibility - All material is copyrighted - You may repost but you MUST link back to the original post on your page and acknowledge Rush PR News as the news source. Rush PR News is not legally and/or morally responsible for content of press releases, opinions expressed or fact-checking.

Rush PR News cannot be held legally responsible for material published and distributed through its newswire service or published in its press-room and therefore cannot be sued for published material. Third-party must be contacted directly to dispute content.

Rush PR News is not the contact for material published.

RSSFeed PRESS & SOCIAL MEDIA RELEASES

Canada-based Hilltop Christmas Tree Farms’ First Tree of the Season Gifted to U.S. Soldier’s Family

Florenceville-Bristol, NB 09/29/16 · Family will celebrate Christmas early before son starts...

Schmid Telecom AG successfully passes SAT at Birmingham Airport

Zurich 09/28/16 · Schmid Telecom AG has successfully completed the Site...

Nexscience LLC Released Document Sign & Send

Santa Clara,CA 09/28/16 · The Document Sign & Send app aims to...

North American leader in food safety certifies Ste Anne’s Spa Bakery

Grafton, ON, Canada 09/28/16 · – For the past 4 years, Ste. Anne's...

DISCOVER THE MULTIMEDIA P.O.R.O.S MUSEUM AND TRAVEL TO PORTUGAL WITH THE INTERNATIONAL SURREALISM NOW 2016

Condeixa-a-Nova 09/28/16 · INTERNATIONAL SURREALISM NOW 2016 An art movement, dedicated...

Dixie Plywood gains insight with Phocas Business Intelligence

Texas 09/27/16 · Since 1944, privately owned and operated Dixie Plywood...

Why and How to Hire a Financial Planner

London, United Kingdom 09/27/16 · Like most people, you probably have hopes and...

Radioactive Waste Management: Global Markets

ALBANY, New York 09/27/16 · Market Research Hub has added a new report,...

NOW SHORTS WITH SECRET POCKETS TO CARRY THINGS WHILE YOU RUN

Ahmedabad 09/27/16 · Anyone who runs or goes out for a...

North American Cities Slow to Adopt Open Source Software

Toronto, ON 09/26/16 · Government IT department are often one of the...

ExeBTC Offers Multiple Investment Packages for Global Investors

Delaware,DE 09/25/16 · For years, ExeBTC has been a leader in...

SchoolFinder to be launched in a new avatar soon

India 09/25/16 · SchoolFinder is pleased to announce that it will...

Leader of New Haven Heroin Ring Pleads Guilty

New Haven,Connecticut 09/22/16 · Deirdre M. Daly, United States Attorney for the...